EUVIMEDEUVIMED entdecken
Multizentrische Studie

High‐dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study

Jun Sik Yoon, Ji Hoon Hong, Soo Young Park iD, Seung Up Kim iD, Hwi Young Kim, Ju Yeon Kim, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Han Ah Lee iD, Gi-Ae Kim iD, Dong Hyun Sinn und 5 weitere

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17909 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Jun Sik Yoon und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea. Hauptthemen laut MEDLINE: Hepatic Encephalopathy, Proton Pump Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Proton pump inhibitors (PPI) are frequently used in patients with cirrhosis.

Aims

This study aimed to determine whether PPI use is associated with the prognosis of cirrhotic patients.

Methods

We conducted a multicentre retrospective cohort study involving 1485 patients who had experienced hepatic encephalopathy (HE) from 7 referral centres in Korea. The primary outcome was overall survival and secondary outcomes included the development of cirrhotic complications, including recurrent HE, spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS), and gastrointestinal bleeding. Patients treated with PPI with a mean defined daily dose (mDDD) ≥0.5 (high‐dose PPI group) were compared to those treated with PPI of an mDDD < 0.5 (No or low‐dose PPI group) for each outcome.

Results

Among 1485 patients (median age, 61 years; male, 61%), 232 were assigned to the high‐dose PPI group. High‐dose PPI use was independently associated with a higher risk of death (adjusted HR [aHR] = 1.71, 95% confidence interval [CI] = 1.38–2.11, p < 0.001). This result was reproducible after propensity score‐matching (PSM) (aHR = 1.90, 95% CI = 1.49–2.44, p < 0.001). High‐dose PPI use was an independent risk factor of recurrent HE (before PSM: aHR = 2.04, 95% CI = 1.66–2.51, p < 0.001; after PSM: aHR = 2.16, 95% CI = 1.70–2.74, p < 0.001), SBP (before PSM: aHR = 1.87, 95% CI = 1.43–2.43, p < 0.001; after PSM: aHR = 1.76, 95% CI = 1.31–2.36, p = 0.002), HRS (before PSM: aHR = 1.48, 95% CI = 1.02–2.15, p = 0.04; after PSM: aHR = 1.47, 95% CI = 0.95–2.28, p = 0.09), and gastrointestinal bleeding (before PSM: aHR = 1.46, 95% CI = 1.12–1.90, p = 0.006; after PSM: aHR = 1.74, 95% CI = 1.28–2.37, p < 0.001).

Conclusions

The use of high‐dose PPI was independently associated with increased risks of mortality and cirrhotic complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatic EncephalopathyProton Pump InhibitorsHumansMaleMiddle AgedGastrointestinal HemorrhageLiver CirrhosisRetrospective StudiesRisk FactorsFemale

Stichwörter der Autor:innen

bacterial translocationhepatic encephalopathymean defined daily dosespontaneous bacterial peritonitis

Substanzen

Proton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.
  • Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea.
  • Department of Internal Medicine and Yonsei Liver Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Republic of Korea.
  • Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Soo Young Park, Seung Up Kim, Han Ah Lee, Gi-Ae Kim, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee

Zitieren

APA

Yoon, J. S., Hong, J. H., Park, S. Y., Kim, S. U., Kim, H. Y., Kim, J. Y., Hur, M. H., Park, M. K., Lee, Y. B., Lee, H. A., Kim, G. A., Sinn, D. H., Park, S. J., Lee, Y. J., Kim, Y. J., Yoon, J. H., & Lee, J. H. (2024). High‐dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17909

Vancouver

Yoon JS, Hong JH, Park SY, Kim SU, Kim HY, Kim JY, et al. High‐dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17909

BibTeX
@article{Yoon2024,
  author = {Yoon, Jun Sik and Hong, Ji Hoon and Park, Soo Young and Kim, Seung Up and Kim, Hwi Young and Kim, Ju Yeon and Hur, Moon Haeng and Park, Min Kyung and Lee, Yun Bin and Lee, Han Ah and Kim, Gi-Ae and Sinn, Dong Hyun and Park, Sung Jae and Lee, Youn Jae and Kim, Yoon Jun and Yoon, Jung-Hwan and Lee, Jeong-Hoon},
  title = {High‐dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17909}
}
Kostenlos starten →